An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis

MicroRNA ◽  
2021 ◽  
Vol 10 ◽  
Author(s):  
Saiedeh Razi Soofiyani ◽  
Kamram Hosseini ◽  
Alireza Soleimanian ◽  
Liela Abkhooei ◽  
Akbar Mohammad Hoseini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Lung Tumor ◽  
Expression Patterns ◽  
Lung Cancer Diagnosis ◽  
Physiological Processes ◽  
Cell Proliferation Inhibition ◽  
Diagnosis Therapy ◽  
Potential Use

: MicroRNAs (miRNAs) are highly conserved non-coding RNAs involved in many physiological processes such as cell proliferation, inhibition, development of apoptosis, differentiation, suppresses tumorigenicity, and regulating cell growth. The description of the alterations of miRNA expression patterns in cancers will be helpful to recognize biomarkers for early detection and possible therapeutic intervention in the treatment of cancers. Recent studies have shown that miR-451 is broadly dysregulated in lung cancer and is a crucial agent in lung tumor progression. This review summarizes recent advances of the potential role of miR-451 in lung cancer diagnosis, prognosis, and treatment and provides an insight into the potential use of miR-451 for the development of advanced therapeutic methods in lung cancer.

scholarly journals p40: A p63 Isoform Useful for Lung Cancer Diagnosis – A Review of the Physiological and Pathological Role of p63

2013 ◽  
Vol 57 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Ana Rita Nobre ◽  
André Albergaria ◽  
Fernando Schmitt
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Lung Cancer Diagnosis

The effect of radiographic emphysema in assessing lung cancer risk

Thorax ◽  
2019 ◽  
Vol 74 (9) ◽  
pp. 858-864 ◽  
Author(s):  
Patrick C Yong ◽  
Keith Sigel ◽  
Juan Pablo de-Torres ◽  
Grace Mhango ◽  
Minal Kale ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Cancer Diagnosis ◽  
Lung Cancer Risk ◽  
Risk Scores ◽  
Risk Models ◽  
Lung Cancer Diagnosis ◽  
National Lung Screening Trial ◽  
Lung Screening

PurposeLung cancer risk models optimise screening by identifying subjects at highest risk, but none of them consider emphysema, a risk factor identifiable on baseline screen. Subjects with a negative baseline low-dose CT (LDCT) screen are at lower risk for subsequent diagnosis and may benefit from risk stratification prior to additional screening, thus we investigated the role of radiographic emphysema as an additional predictor of lung cancer diagnosis in participants with negative baseline LDCT screens of the National Lung Screening Trial.MethodsOur cohorts consist of participants with a negative baseline (T0) LDCT screen (n=16 624) and participants who subsequently had a negative 1-year follow-up (T1) screen (n=14 530). Lung cancer risk scores were calculated using the Bach, PLCOm2012 and Liverpool Lung Project models. Risk of incident lung cancer diagnosis at the end of the study and number screened per incident lung cancer were compared between participants with and without radiographic emphysema.ResultsRadiographic emphysema was independently associated with nearly double the hazard of lung cancer diagnosis at both the second (T1) and third (T2) annual LDCT in all three risk models (HR range 1.9–2.0, p<0.001 for all comparisons). The number screened per incident lung cancer was considerably lower in participants with radiographic emphysema (62 vs 28 at T1 and 91 vs 40 at T2).ConclusionRadiographic emphysema is an independent predictor of lung cancer diagnosis and may help guide decisions surrounding further screening for eligible patients.

Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer

1995 ◽  
Vol 10 (3) ◽  
pp. 156-160 ◽  
Author(s):  
L. Giovanella ◽  
L. Ceriani ◽  
M. Bandera ◽  
B. Beghe ◽  
G. Roncari
Keyword(s):  
Lung Cancer ◽  
Tumor Markers ◽  
Cancer Diagnosis ◽  
Serum Markers ◽  
Successive Treatment ◽  
Disease Extent ◽  
Lung Cancer Diagnosis ◽  
Global Accuracy ◽  
Nsclc Patients

We investigated the role of tumor markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer diagnosis and staging in 169 patients with histologically confirmed lung cancer (43 SCLC and 126 NSCLC). In SCLC patients NSE and CYFRA 21.1 showed the highest senstitivity and their combination improve significantly the diagnostic sensitivity and accuracy. In NSCLC patients CYFRA 21.1 showed the highest sensitivity and global accuracy and no markers association was as effective as CYFRA 21.1 alone. Based on data from our study it can be concluded that in patients with suspected lung cancer the serum NSE and CYFRA 21.1 assay is a suitable association to confirm the clinical hypothesis. NSE in SCLC and CYFRA 21.1 in NSCLC are useful in the evaluation of disease extent and successive treatment planning.

Sign in / Sign up

Export Citation Format

Share Document